Related Experiment Video
Updated: Mar 21, 2026
08:55
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
19.1K
PET/CT in Neuroendocrine Tumors
Paolo Castellucci1, Valentina Ambrosini1, Giancarlo Montini1
1Department of Nuclear Medicine, Policlinico S.Orsola-Malpighi, University of Bologna, Padiglione 30, Via Massarenti 9, 40138 Bologna, Italy.
PET Clinics
|May 10, 2016
Summary
Positron Emission Tomography (PET) offers valuable insights into neuroendocrine tumors (NETs). This review analyzes PET
Area of Science:
- Oncology
- Nuclear Medicine
- Radiopharmaceuticals
Background:
- Neuroendocrine tumors (NETs) are rare neoplasms originating from neuroendocrine cells.
- NETs commonly occur in the bronchus, lungs, or gastroenteropancreatic tract.
Purpose of the Study:
- To review the applications of Positron Emission Tomography (PET) in managing neuroendocrine tumors (NETs).
- To analyze the utility of commonly used radiopharmaceuticals in staging, restaging, and detecting unknown primary NETs.
- To assess the role of PET in monitoring therapy response for various NET treatments.
Main Methods:
- Review of existing literature and studies on PET imaging in NETs.
- Analysis of data concerning receptor and metabolic positron-emitter radiopharmaceuticals.
- Evaluation of PET's effectiveness in different clinical scenarios of NET management.
Main Results:
- PET imaging demonstrates significant potential in staging and restaging NETs.
- PET can aid in detecting unknown primary NETs.
- PET is effective in assessing and monitoring response to various NET therapies.
Conclusions:
- Positron Emission Tomography (PET) is a crucial tool in the comprehensive management of neuroendocrine tumors (NETs).
- The application of receptor and metabolic radiopharmaceuticals in PET enhances diagnostic accuracy and therapeutic monitoring for NET patients.
